Neupro® - Parkinson's disease

Europe

In Europe, Neupro® (rotigotine transdermal patch) is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on-off" fluctuations).

Prescribing information Europe

• SmPC Neupro® (EU) (Sourced from www.ema.europa.eu)

USA

In the US, Neupro® (Rotigotine Transdermal System) is indicated for the treatment of Parkinson's disease.

Related website

• Neupro® product website (for US residents only)

Other countries

For other products not listed in this section please visit the local corporate websites